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Na+,K+-ATPase ligands, also called as cardiotonic steroids, are hormone-like immunoregulators, because they 
are frequently detected in patients with inflammatory-related diseases, moreover, they regulate multiple aspects 
of immune responses. One of prominent roles of Na+,K+-ATPase ligands in regulating immunity is their abilities 
of modulating cytokines expression. These bioactive chemicals can either upregulate or downregulate IL-1β, 
TNF-α, IL6, or iNOS expressions in different model system, however, all of those studies pointed to 
transcriptional upregulation. In our recent studies, we provided evidences that Na+,K+-ATPase ligands are 
capable of regulating cytokines mRNA stability by integrating multiple posttranscriptional mechanisms, 
including human antigen R (HuR) translocation, generation of miR181s, and formation of stress granules. These 
mechanisms do not function alone, but act in a synergistic or an antagonistic manner to fine-tune the cytokines 
expression, HuR nuclear export, however, forms signalosome and plays a core role among these processes. By 
taking advantage of HuR signalosome, Na+,K+-ATPase ligands stabilized cyclooxygenase-2 mRNA in lung 
epithelial cells and induced acute lung injury. In monocytes, ouabain-induced nuclear export of HuR competed 
with miR181s on the shared target of TNF-α, also triggered stress granules formation which recruited TNF-α 
mRNA into it for protection, thereby stabilizing TNF-α mRNA and reversing sepsis-induced immunoparalysis 
both in vitro and in vivo. Besides its effect in immune-related diseases, HuR also regulates a variety of 
pro-oncogenes and anti-oncogenes expressions in cancer cells, which determines the cancer cells sensitivity 
towards Na+,K+-ATPase ligands or other chemotherapeutic drugs. In sum, HuR emerges as a very important 
signaling molecule in Na+,K+-ATPase ligands-mediated cytokines production. These results shed new light on the 
pathophysiologic function as well as pharmacological activities of Na+,K+-ATPase ligands, also highlight a 
fundamental role of Na+,K+-ATPase in regulating cytokine mRNA reprogramming and metabolism. 
Identification of the components of HuR signalosome will offer more novel targets and biomarkers for disease 
therapy. 
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Na+,K+-ATPase ligands are novel hormone-like 
immunomodulators 
Na+,K+-ATPase ligands consist of a family of chemicals 
known to have potent therapeutic value in the therapy of 
cardiovascular diseases. They are not only plant-derived, but 
also produced from amphibian toad or the adrenal cortex and 
hypothalamus in human beings; ouabain is such a good case 
in point. In 1991, Hamlyn and colleagues purified 
endogenous ouabain (EO) from human plasma [1], which 
boosts the investigations for identifying the novel function of 
Na+,K+-ATPase ligands in human physiology or diseases. So 
far, the mainstream is that EO is elevated in patients with 
hypertension[2] or congestive heart failure [3], and is critically 
involved in cardiac remodeling [4]. However, increasing 
evidences demonstrate that EO can also act as a 
hormone-like immunomodulator that regulates immune 
responses[5,6], for instance, ouabain inhibited lymphocyte 
proliferation, exacerbated activation-induced cell death 
(AICD), modulated monocytes, and had remarkable 
anti-inflammatory effects on various inflammatory animal 
models. In fact, ouabain resembles glucocorticoids in many 
aspects of immune regulation, probably because both of them 
share similar core steroid structure and can be released from 
the adrenal under the stimulus of ACTH[7]. However, the 
detailed immunomodulatory mechanisms for Na+,K+-ATPase 
ligands are far from being understood.   
Na+,K+-ATPase ligands regulate cytokines expression in a 
variety of pathological settings 
Cytokines expression profile plays critical roles in the 
progression of pathological diseases. One of prominent roles 
for ouabain in regulating immune responses is its ability of 
modulating cytokines expression. Ouabain was found to 
increase IL-1β, IL-6, and TNF-α expressions in human 
peripheral blood mononuclear cells (PMBC) [8], enhance the 
production of inflammatory cytokines in patients who are 
diagnosed with rheumatoid arthritis[9], and stimulate the 
expressions of VCAM-1 and iNOS in endothelial cells [10]. 
Mesenchymal cells produced abundant GM-CSF in response 
to ouabain treatment, and this effect is dependent on Ca2+ 
increase [11]. Besides, ouabain has an additive effect on 
GM-CSF production induced by TNF-α [12]. Notably, most of 
these studies considered that ouabain regulated cytokines 
expression at transcriptional level. On the contrary, we found 
in recent studies that ouabain had a novel role in regulating 
cytokines expression at posttranscriptional level. Moreover, 
ouabain integrates multiple posttranscriptional mechanisms, 
including microRNAs, RNA binding proteins, stress 
granules, and/or long non-coding RNAs with a purpose of 
delicately controlling cytokines expression, which plays 
pivotal roles in regulating inflammatory process of acute 
lung injury [13], sepsis-induced immunoparalysis [14], and 
cancer cells apoptosis. The following is the detailed review 
of the projects we are currently undertaking.  
Na+,K+-ATPase ligands regulates cyclooxygenase-2 
mRNA stability in acute lung injury-HuR is involved[13] 
Acute lung injury is a frequently-occurring but 
life-threatening pulmonary disease in clinic. Recently, 
increasing evidence demonstrates that Na+, K+-ATPase 
impairment in alveolar epithelial cells is greatly involved in 
the pathogenesis of acute lung injury (ALI) [15]. For example, 
hypoxia trigged the endocytosis and ubiquitin-mediated 
degradation of alveolar epithelial Na+, K+-ATPase, and as a 
result, lung edema clearance is greatly impaired [16].   
Na+, K+-ATPase is a ubiquitously expressed membrane 
ion transporter which maintains the ion and electrolyte 
homeostasis across membrane by consuming ATP supply. In 
light of this, it is not surprising that Na+, K+-ATPase 
impairment in lung epithelial cells inevitably leads to 
inefficient water absorption and lung edema clearance in 
ALI. However, it is noteworthy to mention that ALI is a 
well-characterized inflammatory disorder, whether Na+, 
K+-ATPase impairment also makes a contribution to the 
inflammation of ALI deserves investigation. To solve this 
problem, an acute lung injury model with the impaired Na+, 
K+-ATPase activity in lung is absolutely needed, however, 
because Na+, K+-ATPase is fundamental in physiology, 
knockout of Na+, K+-ATPase gene is expected to cause 
animal death, we thus adopted an alternative strategy by 
using Na+, K+-ATPase inhibitor ouabain. As a result, mice 
inhaled with aerosolized ouabain developed acute 
inflammatory response in lung. However, this pathological 
process was largely alleviated by rofecoxib, suggesting the 
effect of ouabain is dependent on COX-2[13]. In addition to 
ouabain, similar results were also obtained by other 
Na+,K+-ATPase ligands. Meanwhile, it seemed that both 
transcriptional and posttranscriptional layers of regulation 
were involved in COX-2 upregulation by Na+,K+-ATPase 
ligands. Promoter analysis revealed that NF-IL6/c/EBP and 
CRE-binding sites are required for the increased COX-2 gene 
transcription by ouabain.    
Besides transcription, ouabain also persistently increased 
COX-2 mRNA as well as protein expressions over 16 h, 
suggesting additional mechanisms might be involved, 
because COX-2 is a cytokine with short half-life, after 
transcription occurs, COX-2 mRNA will be rapidly degraded 
as a host defense mechanism to eliminate its damaging effect 
on tissues or organs. As a result, the COX-2 transcripts were 
largely prevented from decay by ouabain after they were 
transcribed. Bioinformatics analysis reveals that multiple 
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“AUUUA” element (“AU”-rich elements, ARE) are present 
in the 3’-untranslated region (UTR) of COX-2 transcripts. 
These AREs can be recognized and bound by a variety of 
ARE binding proteins (ARE-BPs) that either increase or 
decrease the half-life of the gene [17]. The well-recognized 
ARE-BPs include human antigen R (HuR), AUF1, TTP, 
KSRP, and so on [18]. Interestingly, ARE-BPs can associate 
with each other and form a complex on the ARE motif, 
thereby delicately controlling the mRNA stability or 
translation efficacy of the target gene[18]. We coined a phrase 
for this way of regulation as ARE-BP signalosome. 
In the study, by constructing a series of deletion variants 
of COX-2 3’-UTR, we finally identified that the sequence of 
Site I ARE largely contributes to COX-2 mRNA stabilization 
in the presence of ouabain treatment. More intriguingly, 
ouabain and other Na+,K+-ATPase ligands can trigger HuR 
translocation from nucleus to cytoplasm, which subsequently 
binds with the sequence of Site I ARE and increases the 
mRNA stability of COX-2 [13].  
This is the first report involving HuR as an important 
RNA binding protein in Na+,K+-ATPase ligands-mediated 
cytokines expression at posttranscriptional level.   
Na+,K+-ATPase ligands regulates tumor necrosis factor α 
mRNA stability in sepsis-induced immunoparalysis 
HuR competes with miR181 and forms stress granules to 
stabilize TNF-α mRNA [14] 
Besides COX-2, lots of other inflammation-related genes 
contain AREs in their 3’-UTRs that can be recognized by 
HuR, such as interleukin 6 (IL6) and various chemokines. 
The aforementioned study raises a possibility that 
Na+,K+-ATPase ligands may regulate the expressions of a 
repertoire of these AREs containing messages as a general 
mechanism. If this is the case, what is the underlying 
mechanisms and biological significance?  
A previous study attracted our attention. In that case, 
ouabain increased TNF-α expression in mononuclear cells 
isolated from patients with rheumatoid arthritis [9]. To 
confirm it, the effects of ouabain and LPS on TNF-α mRNA 
and protein expressions in PBMC and THP1 cell lines were 
examined. Interestingly, both LPS and ouabain were able to 
increase TNF-α mRNA expression in first 2 hours, however, 
the TNF-α mRNA decay in ouabain-treated was significantly 
slowed down as compared to that occurred in LPS-treated 
cells. In PBMC, ouabain treatment even led to persistent 
TNF-α cytokine expression over a 24-h period [14]. These 
results invited us to speculate that ouabain may also regulate 
TNF-α expression at posttranslational level.  
Similar as that of COX-2, the 3’-UTR of TNF-α transcript 
also contains multiple AREs. By constructing deletion 
mutants of TNF-α 3’-UTR, we identified the minimal 
cis-regulatory element (T55) required for ouabain’s effect. 
Notably, unlike that in COX-2 3’-UTR in which the AREs 
are separately distributed, seven “AUUUA” motif sequences 
exactly clustered and overlapped within the T55 region of 
TNF-α 3’-UTR. Ouabain again triggered HuR nuclear export 
in human monocytes, which stabilized TNF-α mRNA. 
However, LPS failed to induce HuR export. Given this result, 
it seems understandable that TNF-α mRNA decay was 
delayed in ouabain-treated cells, but accelerated in 
LPS-treated cells.  
Unexpectedly, T55 region was also found to be the 
minimal cis-regulatory element required for LPS-mediated 
TNF-α destabilization. Targetscan software predicted that a 
highly conserved miR181-binding site (UGAAUGU) is 
present within two adjacent “AUUUA” motif sequences. The 
microRNA181 family consists of four members: miR181a, 
miR181b, miR181c, and miR181d. The “mimics” of 
miR181a/b/c/d greatly reduced the luciferase activity of 
TNF-α 3’-UTR reporter, TNF-α mRNA and protein 
expressions. Moreover, LPS triggered miR181c/d 
transcription through Egr-1 expression. All of these data 
suggest both mRNA stabilizing and destabilizing 
cis-elements co-exist in T55, meanwhile, miR181 is a newly 
identified negative regulator of TNF-α expression.  
More interestingly, ouabain can also trigger 
Egr-1-dependent miR181 production as that of LPS, which is 
conflicting with the fact that ouabain stabilized TNF-α 
mRNA by triggering HuR translocation. To explain this 
inconsistency, we presume that HuR complex may spatially 
mask the binding sites for miR181s in the 3’-UTR of TNF-α. 
This presumption is indeed reasonable, because only one 
miR181 binding site is present in the minimal TNF-α 
3’-UTR; in contrast, seven “AUUUA” motifs are located in 
the immediate vicinity of the miR181 binding site. To 
confirm this hypothesis, we transfected cells with HuR 
expression plasmid, miR181s, and T55 reporter, the results 
clearly demonstrated that there is a competition between 
miR181s and HuR on regulating TNF-α mRNA stability. 
Similar result was also obtained in RNA 
immunoprecipitation experiment. After ouabain treatment, 
the association between HuR and TNF-α mRNA was greatly 
enhanced. In another experiment, we also found that in cells 
after ouabain treatment, many small cytoplasmic foci 
occurred, RNA-FISH experiment revealed that TNF-α 
mRNAs co-localized with these small cytoplasmic organelles 
which were finally identified as stress granules. Therefore, in 
order to stabilize TNF-α mRNA, ouabain integrates multiple 
mechanisms; one is to prevent TNF-α mRNA from 
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nuclease-mediated degradation by triggering HuR nuclear 
export and recruiting them onto the 3’-UTR of TNF-α 
mRNA; the second is to compete the shared target of TNF-α 
mRNA with miR181s, thereby antagonizing the TNF-α 
mRNA destabilizing effect of miR181s; the third is to 
provoke stress granules formation, which recruits TNF-α 
mRNA into it in case of being degraded by miR181s. 
Obviously, HuR integrates different posttranscriptional 
mechanisms and plays a core role in these processes; for 
these characteristics, we assigned it a new name, HuR 
signalosome.  
Ouabain reverses sepsis-induced immunoparalysis by 
reprogramming TH1 cytokines expression  
While we appreciated the role of HuR signalosome in 
ouabain-mediated TNF-α mRNA stabilization, more 
important questions emerge. Why TNF-α mRNA stability is 
needed to be fine-tuned by ouabain? Why the 3’-UTR of 
TNF-α harbors two functionally distinct cis elements in 
regulating TNF-α mRNA stability, and why LPS failed to 
trigger HuR export? To answer these questions, we examined 
the effect of ouabain on sepsis-induced immunoparalysis, 
because TNF-α production is critically involved in this 
pathological disorder; on the other hand, an elevated level of 
EO was detected in patients with severe sepsis, but the 
clinical significance remains unknown.  
Sepsis is a life-threatening disease and normally 
appreciated as a systematic inflammatory response, however, 
clinical therapies that are designed to specifically deactivate 
inflammatory cytokines such as TNF-α and IL-1β antagonists 
have failed, or, in some cases, have worsen the survival[19]. 
Recently, increasing evidence demonstrated that a 
compensatory anti-inflammatory response to 
counter-regulate the immune response in sepsis can result in 
a phase of immunosuppression, which has been convincingly 
established as a major pathogenic mechanism in sepsis[20,21]. 
Sepsis-induced immunosuppression, or called as 
immunoparalysis, is characterized by impaired TNF-α 
production, immune effector cell apoptosis, shift from TH1 to 
a TH2 immune phenotype[20], upregulation of Treg cells, and a 
decrease in human leukocyte antigen-DR (HLA-DR) 
expression in monocytes[22,23]. Unfortunately, the effective 
approach to reverse sepsis-induced immunoparalysis is 
currently not available in clinic. GM-CSF and IFN-γ were 
shown to partially reverse immunoparalysis, but the results 
are only limited to experimental study or small-scale clinical 
trials [24,25].  
In the study, we established a clinically relevant “two-hit” 
model of sepsis that can mimic the pathological setting of 
sepsis-induced immunoparalysis, consisting of cecal ligation 
and puncture (CLP) followed by the induction of Salmonella 
typhimurium (S.tm) infection. In this model, we found 
ouabain significantly improved animal survival when 
administered at a low dose of 0.1 mg/kg at 54 and 78 h 
post-CLP. But surprisingly, when ouabain was administered 
before S.tm infection, at 6 and 30 h after CLP, increased 
mortality was observed. This result suggests that ouabain 
exerts protective effect only at the stage of immunoparalysis, 
but not the stage of hyperinflammation, as such, immune 
status monitoring is necessary for the proper use of ouabain 
in sepsis therapy[14].  
To understand why ouabain was able to reverse 
immunoparalysis, we found the effect of ouabain can be 
largely blocked by infliximab, a TNF-α monoclonal 
antibody, suggesting TNF-α is required for ouabain to have 
effect. This result, indeed, not only explained the necessity of 
increasing TNF-α mRNA stability by ouabain, but also 
highlighted the importance of TNF-α in pathology of 
immunoparalysis.  
Based on different immune characteristic, sepsis can be 
divided into two closely linked immune phases, that is, an 
initial phase of hyperinflammation followed by a subsequent 
phase of immunosuppression[22]. TNF-α has different roles in 
these two phases. At the stage of hyperinflammation, TNF-α 
is massively produced as a major pro-inflammatory cytokine 
to combat bacterial infections; however, the overproduction 
of TNF-α is detrimental to tissue and organ that may lead to 
multiple organs dysfunction. To circumvent this damaging 
effect, host immunity initiates an anti-inflammatory response 
as a defense mechanism to protect itself, which includes the 
production of IL10, TGF-β, and others. Among them, IL10 
was found to decrease TNF-α mRNA stability by 
suppressing p38 MAPK [26]. In this study, miR181s 
production activated by LPS or ouabain can also be 
considered as a host defense mechanism against endotoxin 
injury, because it can potently promote TNF-α mRNA 
degradation. The results from clinical samples also 
confirmed that miR181b/c/d was dramatically upregulated in 
patients with severe sepsis, and accordingly, the TNF-α 
mRNA levels were downregulated.    
  Notably, although miR181s-mediated TNF-α 
degradation is helpful at the stage of hyperinflammation, this 
effect is obviously deleterious at the stage of 
immunoparalysis, because the absence of TNF-α increases 
the risk of secondary infection. In animal experiments, the in 
vivo delivery of cholesterol miR181s significantly reduced 
survival and bacterial clearance in the blood and spleen. The 
antagomir 181 treatment, however, prolonged the survival 
and improved the bacterial clearance. Therefore, it is 
necessary to boost TNF-α expression or restore the impaired 
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TNF-α production at the stage of immunoparalysis. 
Fortunately, ouabain preferentially increased TNF-α 
production in monocytes at the stage of immunoparalysis by 
triggering HuR export and TNF-α mRNA stabilization. In 
this regard, it seems that the miR181 binding site is 
intentionally embedded within “AUUUA” motifs in TNF-α 
3’-UTR by God, which reserves targets for intervention in 
sepsis-induced immunoparalysis. As a matter of fact, besides 
TNF-α, other immunostimulatory cytokines including 
GM-CSF and IFN-γ all contain classic “AUUUA” motifs 
within their 3’-UTR that can be recognized by HuR. In the 
study, ouabain also preferentially stabilized GM-CSF and 
IFN-γ mRNAs in monocytes isolated from sepsis patients. 
GM-CSF and IFN-γ have been shown to reverse 
immunoparalysis by increasing HLA-DR expression in 
monocytes. Consistently, ouabain increased HLA-DR 
expression in monocytes from sepsis patients. Thus, via HuR 
translocation, ouabain may stabilize the mRNAs of many 
immunostimulatory TH1 cytokines, including TNF-α, 
GM-CSF, and IFN-γ, thereby reprogramming cytokine 
expression in the immunosuppressive state and reversing 
immunoparalysis.  
To the best of our knowledge, this is the first report 
demonstrating that a small- molecule drug can reverse 
sepsis-induced immunoparalysis by modulating TNF-α 
mRNA stability, also, the concept that reprogramming 
cytokines expression at posttranscriptional level is helpful for 
reversal of immunoparalysis is proposed for the first time. 
Na+,K+-ATPase ligands regulate both pro-oncogenes and 
anti-oncogenes mRNA stability in cancer cells 
Another important characteristic of Na+,K+-ATPase 
ligands is their potential anti-cancer activities. Many 
Na+,K+-ATPase ligands can trigger cell death in a variety of 
cancerous cell lines in vitro, and have anti-cancer effect in 
vivo[27,28]. Till now, several Na+,K+-ATPase ligands have 
been under phase II trials for cancer therapy in some 
countries[29]. In addition to directly triggering cancer cell 
death, Na+,K+-ATPase ligands are also found to increase 
cancer cells apoptosis sensitivity towards chemotherapeutic 
drugs[29]. For example, Na+,K+-ATPase ligands were found 
to preferentially increase the sensitivity of non-small-cell 
lung carcinoma (NSCLC) cells towards TRAIL-mediated 
apoptosis [30].Interestingly, in our previous investigation, 
suppression of Na+,K+-ATPase activity by ouabain enhanced 
CD95(APO-1)-induced leukemia cell apoptosis, but on the 
other hand, CD95(APO-1) also triggered the endocytosis and 
degradation of membrane Na+,K+-ATPase in CD95-sensitive 
leukemia cells to further augment apoptosis [31]. Suppression 
of Na+,K+-ATPase activity by ouabain also aggravated 
mitochondrial inhibitor-mediated leukemic cell death[32]. 
Apart from these positive effects, contrasting results for 
Na+,K+-ATPase ligands are also frequently reported. For 
example, Na+,K+-ATPase ligands were found to protect cells 
from death, especially when they were used at low 
concentrations, meanwhile, some cancers are refractory to 
Na+,K+-ATPase ligands treatment[29,33].  
It is well recognized that the cancer cells destiny as well as 
their sensitivity towards chemotherapeutic drugs is largely 
determined by expressions of a panel of pro-oncogenes and 
oncogenes. If the effects of anti-oncogenes override the 
effects of pro-oncogenes, the cancer cells are prone to die, or 
becoming sensitive to chemotherapeutic agents. Notably, lots 
of pro-oncogenes and anti-oncogenes contain AREs in their 
3’-UTR. In view of the fact that Na+,K+-ATPase ligands are 
able to trigger HuR translocation, we set out to determine 
whether HuR-mediated posttranscriptional mechanisms are 
also critically involved the effects of Na+,K+-ATPase ligands 
on cancer cells survival or death.  
In our unpublished observations, ouabain-induced HuR 
export stabilized death receptor 5 mRNA, which may explain 
why ouabain was able to increase NSCLC cells apoptotic 
sensitivity towards TRAIL. Surprisingly, low concentration 
of ouabain treatment also posttranscriptionally upregulated 
VEGF expression, which promoted cancer cell growth and 
increased resistance. More intriguingly, we found in a recent 
study that under ouabain treatment, HuR formed stress 
granules and recruited p21 mRNA into them for suppressing 
its pro-apoptotic effect, the HuR-involved stress granules 
formation was regulated by general control non-depressible 
kinase 2 (GCN2). Ouabain enhanced GCN2 protein 
expression by suppressing its degradation machinery 
mediated by β-arrestins and NEDD4L, and this effect was 
relevant to GCN2 phosphorylation at threonine 899, 
moreover, GCN2 had dual roles in regulating cancer cells 
sensitivity towards Na+,K+-ATPase ligands[34]. 
Na+,K+-ATPase ligands and HuR 
In view of the central role of HuR in the effect of ouabain 
on modulating cytokines expression, we tried to understand 
the underlying mechanisms. By generating a series of HuR 
deletion mutants and point mutants, we finally identified that 
serine 88 and serine 158 are critically involved in HuR 
translocation under stimulus of ouabain treatment, however, 
the upstream signaling events that lead to HuR 
phosphorylation still remain as a mystery.  
Concluding remarks 
HuR emerges as a very important signaling molecule in 
Na+,K+-ATPase ligands-mediated effects (Figure 1), which 
opens new avenues for understanding the pathophysiologic 
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and pharmacological effects Na+,K+-ATPase ligands. While 
we appreciated the central role of HuR in these processes, the 
possibilities that other RNA binding proteins involved can 
not be ignored, because HuR does not function alone, it may 
associate with other RNA binding proteins such as AUF1, 
microRNAs, or long non-coding RNAs to form HuR 
signalosome that controls cytokine expression more 
specifically and delicately. Whether those new partners could 
be identified and finally appreciated as novel makers or 
targets for disease therapy remains an intriguing issue. On 
the other hand, increasing evidence demonstrates that 
Na+,K+-ATPase ligands-initiated signaling is either 
Na+,K+-ATPase transport activity dependent or 
independent[6], whether HuR-mediated signaling may 
crosstalk with the well-established Na+,K+-ATPase signaling 
deserves more experiments to verify. 
Finally, although we emphasize here that HuR participates 
in the regulatory effects of Na+,K+-ATPase ligands on 
immunological disorder and cancer, the story is not yet 
complete, because Na+,K+-ATPase ligands are widely 
implicated in a variety of biological processes as 
hormone-like substances. Na+,K+-ATPase is more than an 
ionic pump, that is, besides as a ion pump to exchange 
Na+/K+ across membrane, Na+,K+-ATPase also act as a 
scaffold protein to initiate signaling when they are bound by 
ouabain or other ligands. Here, we identify another 
fundamental role of Na+,K+-ATPase in regulating mRNA 
stability and metabolism. Obviously, as knowledge of RNA 
metabolism increasing, this mechanism, together with others, 
will make us more aware of the complex role of 
Na+,K+-ATPase in human physiology and pathology.  
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